Advertisement
Synosia develops and intends to commercialize innovative and clinicallydifferentiated products for unmet medical needs in psychiatry and neurologyfrom its portfolio of six clinically enabled compounds. To optimize thelikelihood of success, they invited experts known for their impressiveunderstanding of neuroscience, medicine and drug development to join the SABand provide independent assessments of development strategies. Their firstmeeting was in September.
Advertisement
"The distinguished team assembled by Synosia for the Scientific AdvisoryBoard is an extremely well informed group of experts who can provide criticalappraisal of the work the company plans to undertake in the development oftheir impressive portfolio," said J.D. Fitzgerald, FRCP, chairman of the SAB.Dr. Fitzgerald, who has extensive experience in pharmaceutical research anddevelopment, currently serves as a consultant in pharmaceutical research andis a co-founder of Synosia.
The other members of the Synosia SAB are:
- Thomas R. Kosten, M.D., Jay H Waggoner Chair and Professor ofPsychiatry and Neuroscience at Baylor College of Medicine and ResearchDirector of the Veterans Affairs (VA) National Substance Use DisordersQuality Enhancement Research Initiative (QUERI) based at the Houston VA.
- David Grahame-Smith, CBE, FRCP, Emeritus Professor of ClinicalPharmacology, University of Oxford, U.K., author of the Oxford Textbook ofClinical Pharmacology and Drug Therapy and former member of the Committee onthe Safety of Medicine.
- Alan Schatzberg, M.D., Kenneth T. Norris, Jr. Professor and Chairman,Department of Psychiatry and Behavioral Sciences, Stanford University Schoolof Medicine, author of the Manual of Clinical Psychopharmacology and editorof the Textbook of Psychopharmacology.
"We are honored to have such an esteemed group of advisors to help usextend the reach of the compounds in our portfolio into new therapeuticareas," said Synosia Chief Executive Officer and President Ian Massey, Ph.D."Having our work informed by the independent points of view of these expertswill ensure we apply the highest quality of scientific and medical rigor toour development programs."
About Synosia Therapeutics
Synosia Therapeutics develops and intends to commercialize innovative andclinically differentiated products for unmet medical needs in psychiatry andneurology. The privately-owned company is developing six clinical-stagecompounds acquired through key partnerships with Novartis, Roche andSyngenta, including two marketed drugs, that will be tested in newindications extending their reach into new therapeutic areas with combinedsales potential in excess of US$2.5 billion. Synosia has offices in Basel,Switzerland, and South San Francisco, CA.
Synosia Therapeutics has raised US$32.5 million funding from VersantVentures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures(Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information,visit http://www.synosia.com
SOURCE Synosia Therapeutics
